OmniAb to present in vivo discovery technology for radioligand therapy at San Diego summit

OmniAb to present in vivo discovery technology for radioligand therapy at San Diego summit
OmniAb unveils OmniUltra platform

OmniAb announced it will participate in the Targeted Radiopharmaceuticals Summit US 2026 in San Diego. Yasmina Abdiche, PhD and Senior Vice President of Exploratory Research at OmniAb, is set to present the company’s new OmniUltra in vivo discovery platform for structured peptides, targeting radioligand therapy and additional applications.

The event provides OmniAb with an opportunity to showcase innovations in peptide discovery designed to advance targeted therapies in oncology and beyond. The initiative emphasizes the company’s continued focus on research-driven solutions for precision medicine.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.